*At SOUSEIKAI, our Sponsors range from Pharmaceutical, Biologics, Biotech, Vaccine, Generic, and Biosimilar companies, to Medical Device, Nutraceutical, and Tobacco corporations, as well as Universities. These firms vary in size from the largest in the world, to those trying to get a foothold in the Japanese Market for future investment or potential out licensing opportunities. A current approximate ratio of our clientele is 80% Japanese, and 20% foreign.

We believe we are a valuable resource for Sponsors, being able to leverage SOUSEIKAI’s large medical group infrastructure and extended network. Whether it be lending insight on regulatory or study conduction questions; searching for the “right fit” CRO for in-country projects; exploring recruitment PRO resources; looking for academic / KOL knowledge; or being a KOL for investors interested in pursuing projects in Japan – we hope to be both a crucial pivot point for conducting trials, as well as a springboard for helping problem-solve necessary extended resources when needed.

Our specially designed Innovation and Strategic Business Department was crafted with this in mind, helping to streamline communications, reaching out to, and working more closely with, Sponsors. Our efforts include not just outreach in Japan, but as well abroad with clients, and at international conferences and networking events held throughout the world, staying proactive about keeping our finger on the pulse of the latest developments in the industry.

These efforts culminate towards the same goal, for the benefit of all parties – enabling the safest, most time and cost efficient trials, in order to provide the best therapies to those that need it – both here in Japan, and globally.

Please feel free to reach out about your interest in development in Japan, and how we can best serve your goals moving forward!

【Overview】

*SOUSEIKAI Established in 1987

(36 years of clinical trial experience to date)

*5 Clinical research Sites

*360 beds , 350 staff

*Covering a Broad Range of Therapeutic Areas

*for more information about our therapeutic areas, please see the linked page here.

*Study Flexibility – All 5 of our sites are operating under the same SOPs, enabling us to best leverage our manpower and bed-capacity for client projects

【Our Experience】

*130 FIH studies

*Early Phase Specialists Phase 1 -2a

*Full Phase Range from Ph1-Ph4

*Subject Types: Japanese, Caucasian, Korean, Chinese, Post-menapausal Female, Elderly Subjects

*Global Studies , Bridging Studies, POC within 1 protocol

*ICH-GCP Compliance

*for more information about our capabilities, please see the linked page here.

【Support for Sponsors】

*Access to and working with all major CROs, both in Japan and Globally

*Fluent English Speaking staff, for study communication and development support

*Competitive Costs and Pricing

*Study Start-up Reference Timelines (please see chart below)